Novogen Limited (NASDAQ:KZIA) Short Interest Up 56.4% in February

Novogen Limited (NASDAQ:KZIA) was the recipient of a large growth in short interest during the month of February. As of February 13th, there was short interest totaling 48,796 shares, a growth of 56.4% from the January 29th total of 31,200 shares. Currently, 3.0% of the company’s shares are sold short. Based on an average daily trading volume, of 126,006 shares, the short-interest ratio is presently 0.4 days. Based on an average daily trading volume, of 126,006 shares, the short-interest ratio is presently 0.4 days. Currently, 3.0% of the company’s shares are sold short.

Novogen Trading Down 4.5%

NASDAQ KZIA opened at $8.45 on Friday. Novogen has a 12 month low of $2.86 and a 12 month high of $17.40. The stock has a 50-day simple moving average of $6.63 and a 200 day simple moving average of $7.73.

Novogen (NASDAQ:KZIA) last posted its earnings results on Friday, November 7th. The company reported ($6.14) earnings per share (EPS) for the quarter. The firm had revenue of $0.59 million during the quarter.

Analyst Ratings Changes

KZIA has been the topic of several research reports. Wall Street Zen raised Novogen from a “hold” rating to a “buy” rating in a research note on Saturday. HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Novogen in a research report on Wednesday, January 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Novogen in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $19.00.

Novogen Company Profile

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.